Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status Prescription
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 66689-108; 52038-005; 36998-1810; 27808-245; 50228-195; 69539-026; 36998-2477; 67877-733; 68462-678; 14445-012; 65977-0075; 14445-130; 50370-0024; 36998-2478; 68462-681; 65162-925; 47335-922; 69539-025; 0131-5410; 51991-349; 51991-350; 65162-924; 0131-1810; 62331-062; 69539-027; 51991-351; 36998-0119; 36998-2480; 65862-720; 66689-107; 50228-194; 27808-246; 31722-815; 0131-2479; 62332-172; 51991-348; 46708-860; 50228-192; 31722-814; 53296-0101; 0904-7247; 14445-129; 0904-7245; 68462-679; 66689-109; 50228-193; 36998-2479; 17205-107; 25021-791; 13612-0021; 65162-926; 62332-173; 0131-2477; 31722-812; 62332-171; 66651-914; 70166-617; 16436-0101; 67877-735; 14445-406; 14445-132; 66039-882; 67877-736; 0904-7246; 14445-021; 69539-028; 17180-2746; 27808-243; 62332-174; 67877-734; 31722-813; 47335-980; 65372-1186; 0131-2480; 47335-943; 66689-110; 0904-7244; 68225-057; 14445-131; 68462-680; 53747-069; 47335-918; 0131-2478; 27808-244; 12828-0087; 65162-923
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.0010.016759%
Psychiatric symptom19.01.02.0010.010056%Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.030167%Not Available
Psychotic disorder19.03.01.0020.010056%
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Unevaluable event08.01.03.051--Not Available
Sudden unexplained death in epilepsy17.12.03.019; 08.04.01.0120.007870%Not Available
Bone marrow failure01.03.03.005--
Dysmorphism15.11.06.001; 03.11.06.0010.006704%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.006704%Not Available
Type 2 diabetes mellitus05.06.01.003; 14.06.01.003--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.013408%Not Available
Sinus node dysfunction02.03.03.0170.013408%
Arteriovenous malformation24.03.03.020; 03.07.03.0060.001749%Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.002623%Not Available
Impulsive behaviour19.18.01.0010.006704%Not Available
Interruption of aortic arch24.03.03.034; 03.07.08.0070.001749%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.006704%Not Available
Toxic optic neuropathy17.04.05.009; 12.03.01.033; 06.02.08.0030.010056%Not Available
Hypothermia neonatal18.04.06.004; 12.05.03.002; 08.05.01.0070.006704%Not Available
Cell death14.11.02.005; 08.03.03.0030.006704%Not Available
Sopor19.02.04.002; 17.02.04.0210.016759%Not Available
Sputum retention22.02.03.0120.001749%Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages